White label ELPA - ClinicalTrials.eu

Study of Dostarlimab for Patients with High-Risk Locally Advanced Cervical Cancer After Chemo-Radiation

Not recruiting

2 1 1 1
Investigated Diseases:
- Cervix carcinoma
Investigated Drugs:
- Dostarlimab
Study on Elinzanetant for Treating Sleep Disturbances in Menopausal Women

Not recruiting

2 1
Investigated Diseases:
- Menopausal symptoms
- Sleep disorder
Investigated Drugs:
- Elinzanetant
+1
Study on Valbenazine for Patients with Schizophrenia Not Responding Well to Antipsychotic Treatment

Not recruiting

3 1
Investigated Diseases:
- Schizophrenia
Investigated Drugs:
- Valbenazine Ditosylate
Long-term Study of Zanubrutinib for Patients with B-cell Blood Cancer

Not recruiting

3 1 1
Investigated Drugs:
- Zanubrutinib
+3
Study Comparing Loncastuximab Tesirine and Rituximab with Standard Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Not recruiting

3 1 1 1
Investigated Diseases:
- Diffuse large B-cell lymphoma
Investigated Drugs:
+2
Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Not recruiting

3 1 1
Investigated Diseases:
Investigated Drugs:
Study on the Effectiveness of Modified Vaccinia Ankara Vaccine in Preventing Mpox Infection in Adults

Not recruiting

3 1 1 1
Investigated Diseases:
- Monkeypox
Investigated Drugs:
- Modified Vaccinia Ankara – Bavarian Nordic Live Virus
Study on GSK4532990 for Adults with Nonalcoholic Steatohepatitis (NASH)

Not recruiting

2 1
Investigated Diseases:
- Metabolic dysfunction-associated liver disease
Investigated Drugs:
- Gsk4532990A
Study on Osimertinib and Drug Combination for Adults with Unresectable Non-small Cell Lung Cancer

Not recruiting

2 1 1 1
Investigated Drugs:
Study of Ravulizumab for Adults with Lupus Nephritis or IgA Nephropathy

Not recruiting

2 1 1
Investigated Diseases:
- Lupus nephritis
- IgA nephropathy
Investigated Drugs:
- Ravulizumab
+1

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies